{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 196,
   "metadata": {},
   "outputs": [],
   "source": [
    "system_template = f'''Give the names of any location such as city, state, country from the provided sentence in the specified format:\n",
    "---BEGIN FORMAT TEMPLATE---\n",
    "{{\"CITY\":\"city\"\n",
    "\"STATE\":\"state of the city\"\n",
    "\"COUNTRY\": \"the country the city and state belong to\"}}\n",
    "---END FORMAT TEMPLATE---\n",
    "Give the output of the format template in json format\n",
    "'''"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "metadata": {},
   "outputs": [],
   "source": [
    "import threading\n",
    "import time\n",
    "import openai\n",
    "from threading import Lock\n",
    "from langchain_community.embeddings import OpenAIEmbeddings\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "import json\n",
    "from langchain_community.vectorstores import Chroma\n",
    "import pandas as pd\n",
    "\n",
    "class ProcessQuery():\n",
    "    \n",
    "    _instance = None\n",
    "    _lock = Lock()\n",
    "    _query_df = None\n",
    "    \n",
    "    def __new__(cls, *args, **kwargs):\n",
    "        with cls._lock:\n",
    "            if cls._instance is None:\n",
    "                cls._instance = super().__new__(cls)\n",
    "                cls._instance._initialize_vector_db()\n",
    "                cls._instance._initialize_query_df()\n",
    "        return cls._instance\n",
    "    \n",
    "    def _initialize_vector_db(self):\n",
    "        self.vector_database = Chroma(persist_directory='../CT_VDB/VDB_V_01/', embedding_function=OpenAIEmbeddings())\n",
    "        \n",
    "    def _initialize_query_df(self):\n",
    "        if ProcessQuery._query_df is None:\n",
    "            ProcessQuery._query_df = pd.read_csv('../ct_csv/FinalCTTrialsDF_P1_w_ContactInfo.csv')\n",
    "    \n",
    "    def get_nct_scores(self, docs:list) -> dict:\n",
    "        ct_score_dict = {}\n",
    "        for doc in docs:\n",
    "            ct_score_dict[doc[0].metadata['nct_number']] = doc[1]  \n",
    "        return ct_score_dict  \n",
    "    \n",
    "    \n",
    "    def search_vector_db(self, args, result_dict):\n",
    "        vector_db = self.vector_database\n",
    "        result = vector_db.similarity_search_with_relevance_scores(args)\n",
    "        nct_score_dict = self.get_nct_scores(result)\n",
    "        result_dict['vector_db_scores_dict'] = nct_score_dict\n",
    "        result_dict['vector_db_nct_numbers'] = list(nct_score_dict.keys())\n",
    "        \n",
    "        \n",
    "    def get_location(self, system_prompt, user_prompt, model='gpt-4-0125-preview', temperature=0, verbose=False):\n",
    "        response = openai.chat.completions.create(\n",
    "            model=model, \n",
    "            temperature=temperature,\n",
    "            messages=[\n",
    "                {\"role\":\"system\", \"content\":system_prompt},\n",
    "                {\"role\":\"user\", \"content\":str(user_prompt)},\n",
    "            ],\n",
    "            max_tokens = 1024,\n",
    "            response_format={ \"type\": \"json_object\" }\n",
    "            \n",
    "        )\n",
    "        res = response.choices[0].message.content\n",
    "        return res\n",
    "\n",
    "    def search_dataframe(self, args, result_dict):\n",
    "        response = self.get_location(system_prompt=system_template, user_prompt=args)\n",
    "        response_dict = json.loads(response)\n",
    "        result_dict['location'] = response_dict\n",
    "        \n",
    "\n",
    "    @classmethod\n",
    "    def process_query(cls, query:str):\n",
    "        result_dict = {}\n",
    "        vectordb_thread = threading.Thread(target=cls().search_vector_db, args=(query,result_dict))\n",
    "        smart_df_thread = threading.Thread(target=cls().search_dataframe, args=(query,result_dict))\n",
    "        vectordb_thread.start()\n",
    "        smart_df_thread.start()\n",
    "        vectordb_thread.join()\n",
    "        smart_df_thread.join()\n",
    "        query_df = pd.read_csv('../ct_csv/FinalCTTrialsDF_P1_w_ContactInfo.csv')\n",
    "        print(result_dict)\n",
    "        \n",
    "        scores_df = pd.DataFrame.from_dict(result_dict['vector_db_scores_dict'], orient='index', columns=['score'])\n",
    "        scores_df.reset_index(inplace=True)\n",
    "        scores_df.columns = ['NCT_NUMBER', 'score']\n",
    "        \n",
    "        distilled_df = query_df[query_df['NCT_NUMBER'].isin(result_dict['vector_db_nct_numbers'])]\n",
    "        distilled_df = pd.merge(distilled_df, scores_df, on='NCT_NUMBER')\n",
    "\n",
    "        distilled_df = distilled_df.sort_values(by='score', ascending=False)\n",
    "        \n",
    "        distilled_df.to_csv('../result_tests/result.csv')\n",
    "        \n",
    "        if len(distilled_df[distilled_df['CITY'] == result_dict['location']['CITY']]):\n",
    "            distilled_df = distilled_df[distilled_df['CITY'] == result_dict['location']['CITY']]\n",
    "        elif len(distilled_df[distilled_df['STATE'] == result_dict['location']['STATE']]):\n",
    "            distilled_df = distilled_df[distilled_df['STATE'] == result_dict['location']['STATE']]\n",
    "        elif len(distilled_df[distilled_df['COUNTRY'] == result_dict['location']['COUNTRY']]):\n",
    "            distilled_df = distilled_df[distilled_df['COUNTRY'] == result_dict['location']['COUNTRY']]\n",
    "        # else:\n",
    "        #     distilled_df = {}\n",
    "        return distilled_df\n",
    "    \n",
    "    \n",
    "    def __init__(self):\n",
    "        self.return_value = None"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>FACILITY</th>\n",
       "      <th>CITY</th>\n",
       "      <th>STATE</th>\n",
       "      <th>ZIP</th>\n",
       "      <th>COUNTRY</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>274</td>\n",
       "      <td>274</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Kaiser Permanente-Capitol Hill Medical Center</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>275</td>\n",
       "      <td>275</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>276</td>\n",
       "      <td>276</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>MedStar Washington Hospital Center</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20010</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td>394</td>\n",
       "      <td>394</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>724</th>\n",
       "      <td>724</td>\n",
       "      <td>724</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Mercy Hospital Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63090</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16622</th>\n",
       "      <td>16622</td>\n",
       "      <td>16622</td>\n",
       "      <td>NCT05836584</td>\n",
       "      <td>Testing Immunotherapy (Atezolizumab) With or W...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05836584</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical Stage I Gastric Cancer AJCC v8, Clini...</td>\n",
       "      <td>June 8, 2024</td>\n",
       "      <td>October 31, 2027</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome measure is event-free surv...</td>\n",
       "      <td>Secondary outcomes include tumor regression gr...</td>\n",
       "      <td>Interventions involve two experimental arms. A...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16952</th>\n",
       "      <td>16952</td>\n",
       "      <td>16952</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17019</th>\n",
       "      <td>17019</td>\n",
       "      <td>17019</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17208</th>\n",
       "      <td>17208</td>\n",
       "      <td>17208</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>Mercy Hospital Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63090</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17538</th>\n",
       "      <td>17538</td>\n",
       "      <td>17538</td>\n",
       "      <td>NCT05254171</td>\n",
       "      <td>Study of Nab-Paclitaxel and Gemcitabine With o...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05254171</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer Metastatic, Pancreatic Ducta...</td>\n",
       "      <td>August 8, 2022</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults ≥18 years with his...</td>\n",
       "      <td>The primary outcome is to compare Overall Surv...</td>\n",
       "      <td>Secondary outcomes include comparing Progressi...</td>\n",
       "      <td>Interventions include SBP-101, a small molecul...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>67 rows × 19 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "274             274         274  NCT04267848   \n",
       "275             275         275  NCT04267848   \n",
       "276             276         276  NCT04267848   \n",
       "394             394         394  NCT04267848   \n",
       "724             724         724  NCT04267848   \n",
       "...             ...         ...          ...   \n",
       "16622         16622       16622  NCT05836584   \n",
       "16952         16952       16952  NCT03866382   \n",
       "17019         17019       17019  NCT03866382   \n",
       "17208         17208       17208  NCT03866382   \n",
       "17538         17538       17538  NCT05254171   \n",
       "\n",
       "                                             STUDY_TITLE  \\\n",
       "274    Testing the Addition of a Type of Drug Called ...   \n",
       "275    Testing the Addition of a Type of Drug Called ...   \n",
       "276    Testing the Addition of a Type of Drug Called ...   \n",
       "394    Testing the Addition of a Type of Drug Called ...   \n",
       "724    Testing the Addition of a Type of Drug Called ...   \n",
       "...                                                  ...   \n",
       "16622  Testing Immunotherapy (Atezolizumab) With or W...   \n",
       "16952  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17019  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17208  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17538  Study of Nab-Paclitaxel and Gemcitabine With o...   \n",
       "\n",
       "                                              STUDY_URL STUDY_STATUS  \\\n",
       "274    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "275    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "276    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "394    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "724    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "...                                                 ...          ...   \n",
       "16622  https://www.clinicaltrials.gov/study/NCT05836584   Recruiting   \n",
       "16952  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17019  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17208  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17538  https://www.clinicaltrials.gov/study/NCT05254171   Recruiting   \n",
       "\n",
       "                                              CONDITIONS      START_DATE  \\\n",
       "274    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "275    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "276    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "394    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "724    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "...                                                  ...             ...   \n",
       "16622  Clinical Stage I Gastric Cancer AJCC v8, Clini...    June 8, 2024   \n",
       "16952  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17019  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17208  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17538  Pancreatic Cancer Metastatic, Pancreatic Ducta...  August 8, 2022   \n",
       "\n",
       "         COMPLETION_DATE                          AGE  \\\n",
       "274    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "275    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "276    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "394    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "724    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "...                  ...                          ...   \n",
       "16622   October 31, 2027  18 Years||Adult|Older Adult   \n",
       "16952  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17019  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17208  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17538       May 31, 2024  18 Years||Adult|Older Adult   \n",
       "\n",
       "                                    ELIGIBILITY_CRITERIA  \\\n",
       "274    Eligibility includes: sexually mature females ...   \n",
       "275    Eligibility includes: sexually mature females ...   \n",
       "276    Eligibility includes: sexually mature females ...   \n",
       "394    Eligibility includes: sexually mature females ...   \n",
       "724    Eligibility includes: sexually mature females ...   \n",
       "...                                                  ...   \n",
       "16622  Eligibility includes individuals 18 years or o...   \n",
       "16952  Eligibility includes individuals 18 years or o...   \n",
       "17019  Eligibility includes individuals 18 years or o...   \n",
       "17208  Eligibility includes individuals 18 years or o...   \n",
       "17538  Eligibility includes adults ≥18 years with his...   \n",
       "\n",
       "                                        PRIMARY_OUTCOMES  \\\n",
       "274    The primary outcome is to compare disease-free...   \n",
       "275    The primary outcome is to compare disease-free...   \n",
       "276    The primary outcome is to compare disease-free...   \n",
       "394    The primary outcome is to compare disease-free...   \n",
       "724    The primary outcome is to compare disease-free...   \n",
       "...                                                  ...   \n",
       "16622  The primary outcome measure is event-free surv...   \n",
       "16952  The primary outcome is the Objective Response ...   \n",
       "17019  The primary outcome is the Objective Response ...   \n",
       "17208  The primary outcome is the Objective Response ...   \n",
       "17538  The primary outcome is to compare Overall Surv...   \n",
       "\n",
       "                                      SECONDARY_OUTCOMES  \\\n",
       "274    Secondary outcomes include overall survival (O...   \n",
       "275    Secondary outcomes include overall survival (O...   \n",
       "276    Secondary outcomes include overall survival (O...   \n",
       "394    Secondary outcomes include overall survival (O...   \n",
       "724    Secondary outcomes include overall survival (O...   \n",
       "...                                                  ...   \n",
       "16622  Secondary outcomes include tumor regression gr...   \n",
       "16952  Secondary outcomes include the duration of res...   \n",
       "17019  Secondary outcomes include the duration of res...   \n",
       "17208  Secondary outcomes include the duration of res...   \n",
       "17538  Secondary outcomes include comparing Progressi...   \n",
       "\n",
       "                                           INTERVENTIONS  \\\n",
       "274    Interventions include biospecimen collection, ...   \n",
       "275    Interventions include biospecimen collection, ...   \n",
       "276    Interventions include biospecimen collection, ...   \n",
       "394    Interventions include biospecimen collection, ...   \n",
       "724    Interventions include biospecimen collection, ...   \n",
       "...                                                  ...   \n",
       "16622  Interventions involve two experimental arms. A...   \n",
       "16952  Participants will receive cabozantinib orally,...   \n",
       "17019  Participants will receive cabozantinib orally,...   \n",
       "17208  Participants will receive cabozantinib orally,...   \n",
       "17538  Interventions include SBP-101, a small molecul...   \n",
       "\n",
       "                                            FACILITY        CITY     STATE  \\\n",
       "274    Kaiser Permanente-Capitol Hill Medical Center  Washington        DC   \n",
       "275           MedStar Georgetown University Hospital  Washington        DC   \n",
       "276               MedStar Washington Hospital Center  Washington        DC   \n",
       "394                 Illinois CancerCare - Washington  Washington  Illinois   \n",
       "724                        Mercy Hospital Washington  Washington  Missouri   \n",
       "...                                              ...         ...       ...   \n",
       "16622               Illinois CancerCare - Washington  Washington  Illinois   \n",
       "16952         MedStar Georgetown University Hospital  Washington        DC   \n",
       "17019               Illinois CancerCare - Washington  Washington  Illinois   \n",
       "17208                      Mercy Hospital Washington  Washington  Missouri   \n",
       "17538         MedStar Georgetown University Hospital  Washington        DC   \n",
       "\n",
       "         ZIP        COUNTRY  \n",
       "274    20002  United States  \n",
       "275    20007  United States  \n",
       "276    20010  United States  \n",
       "394    61571  United States  \n",
       "724    63090  United States  \n",
       "...      ...            ...  \n",
       "16622  61571  United States  \n",
       "16952  20007  United States  \n",
       "17019  61571  United States  \n",
       "17208  63090  United States  \n",
       "17538  20007  United States  \n",
       "\n",
       "[67 rows x 19 columns]"
      ]
     },
     "execution_count": 195,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/Users/suryabhosale/Documents/projects/DORIS/src/POCClinicalTrial/CT_SEARCH_METHODS/hybrid_v1/FinalCTTrialsDF_P1.csv')\n",
    "df[df['CITY'] == 'Washington']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'vector_db_scores_dict': {'NCT06072612': 0.7684220756613157, 'NCT03213925': 0.7608751977466823, 'NCT04925856': 0.760379866909558, 'NCT05872347': 0.7560558742068556}, 'vector_db_nct_numbers': ['NCT06072612', 'NCT03213925', 'NCT04925856', 'NCT05872347'], 'location': {'CITY': 'Irvine', 'STATE': 'California', 'COUNTRY': 'United States'}}\n"
     ]
    }
   ],
   "source": [
    "items = ProcessQuery.process_query(\"What are potential clinical trial options for a patient with metastatic breast cancer in Irvine area?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'vector_db_scores_dict': {'NCT06072612': 0.7684220756613157, 'NCT03213925': 0.7608751977466823, 'NCT04925856': 0.760379866909558, 'NCT05872347': 0.7560558742068556}, 'vector_db_nct_numbers': ['NCT06072612', 'NCT03213925', 'NCT04925856', 'NCT05872347'], 'location': {'CITY': 'Irvine', 'STATE': 'California', 'COUNTRY': 'United States'}}\n"
     ]
    }
   ],
   "source": [
    "items = ProcessQuery.process_query(\"What are potential clinical trial options for a patient with metastatic breast cancer in Irvine area?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.2</th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>...</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>FACILITY</th>\n",
       "      <th>CITY</th>\n",
       "      <th>STATE</th>\n",
       "      <th>ZIP</th>\n",
       "      <th>COUNTRY</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>10664</td>\n",
       "      <td>10664</td>\n",
       "      <td>10664</td>\n",
       "      <td>NCT06072612</td>\n",
       "      <td>Study of the Bria-IMT Regimen and CPI vs Physi...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT06072612</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Breast Cancer, Metastatic Breast Cancer, Breas...</td>\n",
       "      <td>October 20, 2023</td>\n",
       "      <td>December 2025</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is to assess the effect of...</td>\n",
       "      <td>Secondary outcomes include evaluating the Bria...</td>\n",
       "      <td>Interventions include the Bria-IMT regimen (Da...</td>\n",
       "      <td>New York Cancers &amp; Blood Specialists</td>\n",
       "      <td>Port Jefferson Station</td>\n",
       "      <td>New York</td>\n",
       "      <td>11776</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.768422</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows × 22 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Unnamed: 0.2  Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "40         10664         10664       10664  NCT06072612   \n",
       "\n",
       "                                          STUDY_TITLE  \\\n",
       "40  Study of the Bria-IMT Regimen and CPI vs Physi...   \n",
       "\n",
       "                                           STUDY_URL STUDY_STATUS  \\\n",
       "40  https://www.clinicaltrials.gov/study/NCT06072612   Recruiting   \n",
       "\n",
       "                                           CONDITIONS        START_DATE  \\\n",
       "40  Breast Cancer, Metastatic Breast Cancer, Breas...  October 20, 2023   \n",
       "\n",
       "   COMPLETION_DATE  ...                                   PRIMARY_OUTCOMES  \\\n",
       "40   December 2025  ...  The primary outcome is to assess the effect of...   \n",
       "\n",
       "                                   SECONDARY_OUTCOMES  \\\n",
       "40  Secondary outcomes include evaluating the Bria...   \n",
       "\n",
       "                                        INTERVENTIONS  \\\n",
       "40  Interventions include the Bria-IMT regimen (Da...   \n",
       "\n",
       "                                FACILITY                    CITY     STATE  \\\n",
       "40  New York Cancers & Blood Specialists  Port Jefferson Station  New York   \n",
       "\n",
       "      ZIP        COUNTRY                                   POINT_OF_CONTACT  \\\n",
       "40  11776  United States  {'Name': None, 'Organization': None, 'Email': ...   \n",
       "\n",
       "       score  \n",
       "40  0.768422  \n",
       "\n",
       "[1 rows x 22 columns]"
      ]
     },
     "execution_count": 200,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "items"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 202,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_payload = pd.DataFrame(items, columns=items.columns).to_json(orient='records')\n",
    "json_payload_dict = json.loads(json_payload)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 203,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'Unnamed: 0.2': 10664,\n",
       "  'Unnamed: 0.1': 10664,\n",
       "  'Unnamed: 0': 10664,\n",
       "  'NCT_NUMBER': 'NCT06072612',\n",
       "  'STUDY_TITLE': \"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.\",\n",
       "  'STUDY_URL': 'https://www.clinicaltrials.gov/study/NCT06072612',\n",
       "  'STUDY_STATUS': 'Recruiting',\n",
       "  'CONDITIONS': 'Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer',\n",
       "  'START_DATE': 'October 20, 2023',\n",
       "  'COMPLETION_DATE': 'December 2025',\n",
       "  'AGE': '18 Years||Adult|Older Adult',\n",
       "  'ELIGIBILITY_CRITERIA': 'Eligibility includes individuals aged 18 or older with histologically confirmed breast cancer, either locally recurrent unresectable/metastatic, having failed prior therapy. Specific requirements vary by cancer subtype, including treatment history for HER2 positive, ER/PR positive, triple-negative, and HER2 low tumors. Brain metastases must be stable, with no steroids for 2 weeks prior to the first dose. Exclusions cover recent chemotherapy, immunotherapy, major surgery, radiotherapy, unresolved toxicity from prior therapy, certain lab value abnormalities, uncontrolled HIV/AIDS, active autoimmune disease requiring systemic treatment in the past year, pregnancy, nursing, other malignancies within 2 years, and severe psychiatric disease.',\n",
       "  'PRIMARY_OUTCOMES': \"The primary outcome is to assess the effect of the Bria-IMT regimen in combination with a Check Point Inhibitor (CPI) on overall survival (OS) compared to the treatment of physician's choice (TPC) chemotherapy in patients with metastatic breast cancer who have no approved alternative therapies available. The evaluation timeframe for this outcome is up to 60 months.\",\n",
       "  'SECONDARY_OUTCOMES': 'Secondary outcomes include evaluating the Bria-IMT regimen with CPI on progression-free survival (PFS), assessing single-agent activity using PFS, ORR, and CBR, evaluating efficacy using Clinical Benefit Rate (CBR) and best overall response rate (ORR), and comparing the effect on quality of life (QoL), including time without symptoms and toxicities. The evaluation timeframe for these outcomes is up to 60 months.',\n",
       "  'INTERVENTIONS': \"Interventions include the Bria-IMT regimen (Day -2 Cyclophosphamide 300mg/m2, Day 0 SV-BR-1-GM intradermally, Day 1-3 CPI infusion plus interferon intra-dermally at inoculation sites) alone or with CPI (Retifanlimab), and the Treatment of Physician's Choice (TPC) arm with options like eribulin, carboplatin, capecitabine, gemcitabine, vinorelbine, or taxanes, tailored to the investigator's and institutional standard of care. SV-BR-1-GM is an experimental breast tumor cell line designed to augment dendritic cell activity, and Cyclophosphamide is an alkylating agent for treating malignant diseases including breast cancer.\",\n",
       "  'FACILITY': 'New York Cancers & Blood Specialists',\n",
       "  'CITY': 'Port Jefferson Station',\n",
       "  'STATE': 'New York',\n",
       "  'ZIP': '11776',\n",
       "  'COUNTRY': 'United States',\n",
       "  'POINT_OF_CONTACT': \"{'Name': None, 'Organization': None, 'Email': None, 'Phone': None}\",\n",
       "  'score': 0.7684220757}]"
      ]
     },
     "execution_count": 203,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json_payload_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 201,
   "metadata": {},
   "outputs": [],
   "source": [
    "values_dict = {'vector_db_scores_dict': {'NCT03191149': 0.797766271027995, 'NCT03865511': 0.78732116507551, 'NCT04335292': 0.7868135905788933, 'NCT04780568': 0.7826158698343295}, 'vector_db_nct_numbers': ['NCT03191149', 'NCT03865511', 'NCT04335292', 'NCT04780568'], 'location': {'CITY': 'Chicago', 'STATE': 'Illinois', 'COUNTRY': 'United States'}}\n",
    "\n",
    "\n",
    "\n",
    "scores_df = pd.DataFrame.from_dict(values_dict['vector_db_scores_dict'], orient='index', columns=['score'])\n",
    "scores_df.reset_index(inplace=True)\n",
    "scores_df.columns = ['NCT_NUMBER', 'score']\n",
    "\n",
    "# # Filter final DataFrame based on vector_db_nct_numbers\n",
    "final_df = pd.read_csv('../ct_csv/FinalCTTrialsDF_P1.csv')\n",
    "# final_df = final_df[final_df['NCT_NUMBER'].isin(values_dict['vector_db_nct_numbers'])]\n",
    "\n",
    "# # # Merge final DataFrame with scores DataFrame\n",
    "# final_df = pd.merge(final_df, scores_df, on='NCT_NUMBER')\n",
    "\n",
    "# # # # Sort DataFrame based on scores\n",
    "# final_df = final_df.sort_values(by='score', ascending=False)\n",
    "\n",
    "# city_df = final_df[final_df['CITY'] == values_dict['location']['CITY']]\n",
    "# state_df = final_df[final_df['STATE'] == values_dict['location']['STATE']]\n",
    "# country_df = final_df[final_df['COUNTRY'] == values_dict['location']['COUNTRY']]\n",
    "\n",
    "# # Concatenate DataFrames and drop duplicates\n",
    "# final_df = pd.concat([city_df, state_df, country_df])\n",
    "# final_df = final_df.drop_duplicates(subset='NCT_NUMBER', keep='first')\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 169,
   "metadata": {},
   "outputs": [],
   "source": [
    "name_change_dict = {'District of Columbia':'DC'}\n",
    "final_df['STATE'].replace(name_change_dict, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 173,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>COMPLETION_DATE</th>\n",
       "      <th>AGE</th>\n",
       "      <th>ELIGIBILITY_CRITERIA</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>FACILITY</th>\n",
       "      <th>CITY</th>\n",
       "      <th>STATE</th>\n",
       "      <th>ZIP</th>\n",
       "      <th>COUNTRY</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>274</th>\n",
       "      <td>274</td>\n",
       "      <td>274</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Kaiser Permanente-Capitol Hill Medical Center</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20002</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>275</th>\n",
       "      <td>275</td>\n",
       "      <td>275</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>276</th>\n",
       "      <td>276</td>\n",
       "      <td>276</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>MedStar Washington Hospital Center</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20010</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>394</th>\n",
       "      <td>394</td>\n",
       "      <td>394</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>724</th>\n",
       "      <td>724</td>\n",
       "      <td>724</td>\n",
       "      <td>NCT04267848</td>\n",
       "      <td>Testing the Addition of a Type of Drug Called ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04267848</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Lung Non-Small Cell Carcinoma, Lung Non-Small ...</td>\n",
       "      <td>June 16, 2020</td>\n",
       "      <td>December 15, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes: sexually mature females ...</td>\n",
       "      <td>The primary outcome is to compare disease-free...</td>\n",
       "      <td>Secondary outcomes include overall survival (O...</td>\n",
       "      <td>Interventions include biospecimen collection, ...</td>\n",
       "      <td>Mercy Hospital Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63090</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16622</th>\n",
       "      <td>16622</td>\n",
       "      <td>16622</td>\n",
       "      <td>NCT05836584</td>\n",
       "      <td>Testing Immunotherapy (Atezolizumab) With or W...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05836584</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Clinical Stage I Gastric Cancer AJCC v8, Clini...</td>\n",
       "      <td>June 8, 2024</td>\n",
       "      <td>October 31, 2027</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome measure is event-free surv...</td>\n",
       "      <td>Secondary outcomes include tumor regression gr...</td>\n",
       "      <td>Interventions involve two experimental arms. A...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16952</th>\n",
       "      <td>16952</td>\n",
       "      <td>16952</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17019</th>\n",
       "      <td>17019</td>\n",
       "      <td>17019</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>Illinois CancerCare - Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Illinois</td>\n",
       "      <td>61571</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17208</th>\n",
       "      <td>17208</td>\n",
       "      <td>17208</td>\n",
       "      <td>NCT03866382</td>\n",
       "      <td>Testing the Effectiveness of Two Immunotherapy...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03866382</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Bladder Adenocarcinoma, Bladder Clear Cell Ade...</td>\n",
       "      <td>May 13, 2019</td>\n",
       "      <td>February 28, 2025</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes individuals 18 years or o...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include the duration of res...</td>\n",
       "      <td>Participants will receive cabozantinib orally,...</td>\n",
       "      <td>Mercy Hospital Washington</td>\n",
       "      <td>Washington</td>\n",
       "      <td>Missouri</td>\n",
       "      <td>63090</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17538</th>\n",
       "      <td>17538</td>\n",
       "      <td>17538</td>\n",
       "      <td>NCT05254171</td>\n",
       "      <td>Study of Nab-Paclitaxel and Gemcitabine With o...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT05254171</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Pancreatic Cancer Metastatic, Pancreatic Ducta...</td>\n",
       "      <td>August 8, 2022</td>\n",
       "      <td>May 31, 2024</td>\n",
       "      <td>18 Years||Adult|Older Adult</td>\n",
       "      <td>Eligibility includes adults ≥18 years with his...</td>\n",
       "      <td>The primary outcome is to compare Overall Surv...</td>\n",
       "      <td>Secondary outcomes include comparing Progressi...</td>\n",
       "      <td>Interventions include SBP-101, a small molecul...</td>\n",
       "      <td>MedStar Georgetown University Hospital</td>\n",
       "      <td>Washington</td>\n",
       "      <td>DC</td>\n",
       "      <td>20007</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>67 rows × 19 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "       Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "274             274         274  NCT04267848   \n",
       "275             275         275  NCT04267848   \n",
       "276             276         276  NCT04267848   \n",
       "394             394         394  NCT04267848   \n",
       "724             724         724  NCT04267848   \n",
       "...             ...         ...          ...   \n",
       "16622         16622       16622  NCT05836584   \n",
       "16952         16952       16952  NCT03866382   \n",
       "17019         17019       17019  NCT03866382   \n",
       "17208         17208       17208  NCT03866382   \n",
       "17538         17538       17538  NCT05254171   \n",
       "\n",
       "                                             STUDY_TITLE  \\\n",
       "274    Testing the Addition of a Type of Drug Called ...   \n",
       "275    Testing the Addition of a Type of Drug Called ...   \n",
       "276    Testing the Addition of a Type of Drug Called ...   \n",
       "394    Testing the Addition of a Type of Drug Called ...   \n",
       "724    Testing the Addition of a Type of Drug Called ...   \n",
       "...                                                  ...   \n",
       "16622  Testing Immunotherapy (Atezolizumab) With or W...   \n",
       "16952  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17019  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17208  Testing the Effectiveness of Two Immunotherapy...   \n",
       "17538  Study of Nab-Paclitaxel and Gemcitabine With o...   \n",
       "\n",
       "                                              STUDY_URL STUDY_STATUS  \\\n",
       "274    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "275    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "276    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "394    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "724    https://www.clinicaltrials.gov/study/NCT04267848   Recruiting   \n",
       "...                                                 ...          ...   \n",
       "16622  https://www.clinicaltrials.gov/study/NCT05836584   Recruiting   \n",
       "16952  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17019  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17208  https://www.clinicaltrials.gov/study/NCT03866382   Recruiting   \n",
       "17538  https://www.clinicaltrials.gov/study/NCT05254171   Recruiting   \n",
       "\n",
       "                                              CONDITIONS      START_DATE  \\\n",
       "274    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "275    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "276    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "394    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "724    Lung Non-Small Cell Carcinoma, Lung Non-Small ...   June 16, 2020   \n",
       "...                                                  ...             ...   \n",
       "16622  Clinical Stage I Gastric Cancer AJCC v8, Clini...    June 8, 2024   \n",
       "16952  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17019  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17208  Bladder Adenocarcinoma, Bladder Clear Cell Ade...    May 13, 2019   \n",
       "17538  Pancreatic Cancer Metastatic, Pancreatic Ducta...  August 8, 2022   \n",
       "\n",
       "         COMPLETION_DATE                          AGE  \\\n",
       "274    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "275    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "276    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "394    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "724    December 15, 2024  18 Years||Adult|Older Adult   \n",
       "...                  ...                          ...   \n",
       "16622   October 31, 2027  18 Years||Adult|Older Adult   \n",
       "16952  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17019  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17208  February 28, 2025  18 Years||Adult|Older Adult   \n",
       "17538       May 31, 2024  18 Years||Adult|Older Adult   \n",
       "\n",
       "                                    ELIGIBILITY_CRITERIA  \\\n",
       "274    Eligibility includes: sexually mature females ...   \n",
       "275    Eligibility includes: sexually mature females ...   \n",
       "276    Eligibility includes: sexually mature females ...   \n",
       "394    Eligibility includes: sexually mature females ...   \n",
       "724    Eligibility includes: sexually mature females ...   \n",
       "...                                                  ...   \n",
       "16622  Eligibility includes individuals 18 years or o...   \n",
       "16952  Eligibility includes individuals 18 years or o...   \n",
       "17019  Eligibility includes individuals 18 years or o...   \n",
       "17208  Eligibility includes individuals 18 years or o...   \n",
       "17538  Eligibility includes adults ≥18 years with his...   \n",
       "\n",
       "                                        PRIMARY_OUTCOMES  \\\n",
       "274    The primary outcome is to compare disease-free...   \n",
       "275    The primary outcome is to compare disease-free...   \n",
       "276    The primary outcome is to compare disease-free...   \n",
       "394    The primary outcome is to compare disease-free...   \n",
       "724    The primary outcome is to compare disease-free...   \n",
       "...                                                  ...   \n",
       "16622  The primary outcome measure is event-free surv...   \n",
       "16952  The primary outcome is the Objective Response ...   \n",
       "17019  The primary outcome is the Objective Response ...   \n",
       "17208  The primary outcome is the Objective Response ...   \n",
       "17538  The primary outcome is to compare Overall Surv...   \n",
       "\n",
       "                                      SECONDARY_OUTCOMES  \\\n",
       "274    Secondary outcomes include overall survival (O...   \n",
       "275    Secondary outcomes include overall survival (O...   \n",
       "276    Secondary outcomes include overall survival (O...   \n",
       "394    Secondary outcomes include overall survival (O...   \n",
       "724    Secondary outcomes include overall survival (O...   \n",
       "...                                                  ...   \n",
       "16622  Secondary outcomes include tumor regression gr...   \n",
       "16952  Secondary outcomes include the duration of res...   \n",
       "17019  Secondary outcomes include the duration of res...   \n",
       "17208  Secondary outcomes include the duration of res...   \n",
       "17538  Secondary outcomes include comparing Progressi...   \n",
       "\n",
       "                                           INTERVENTIONS  \\\n",
       "274    Interventions include biospecimen collection, ...   \n",
       "275    Interventions include biospecimen collection, ...   \n",
       "276    Interventions include biospecimen collection, ...   \n",
       "394    Interventions include biospecimen collection, ...   \n",
       "724    Interventions include biospecimen collection, ...   \n",
       "...                                                  ...   \n",
       "16622  Interventions involve two experimental arms. A...   \n",
       "16952  Participants will receive cabozantinib orally,...   \n",
       "17019  Participants will receive cabozantinib orally,...   \n",
       "17208  Participants will receive cabozantinib orally,...   \n",
       "17538  Interventions include SBP-101, a small molecul...   \n",
       "\n",
       "                                            FACILITY        CITY     STATE  \\\n",
       "274    Kaiser Permanente-Capitol Hill Medical Center  Washington        DC   \n",
       "275           MedStar Georgetown University Hospital  Washington        DC   \n",
       "276               MedStar Washington Hospital Center  Washington        DC   \n",
       "394                 Illinois CancerCare - Washington  Washington  Illinois   \n",
       "724                        Mercy Hospital Washington  Washington  Missouri   \n",
       "...                                              ...         ...       ...   \n",
       "16622               Illinois CancerCare - Washington  Washington  Illinois   \n",
       "16952         MedStar Georgetown University Hospital  Washington        DC   \n",
       "17019               Illinois CancerCare - Washington  Washington  Illinois   \n",
       "17208                      Mercy Hospital Washington  Washington  Missouri   \n",
       "17538         MedStar Georgetown University Hospital  Washington        DC   \n",
       "\n",
       "         ZIP        COUNTRY  \n",
       "274    20002  United States  \n",
       "275    20007  United States  \n",
       "276    20010  United States  \n",
       "394    61571  United States  \n",
       "724    63090  United States  \n",
       "...      ...            ...  \n",
       "16622  61571  United States  \n",
       "16952  20007  United States  \n",
       "17019  61571  United States  \n",
       "17208  63090  United States  \n",
       "17538  20007  United States  \n",
       "\n",
       "[67 rows x 19 columns]"
      ]
     },
     "execution_count": 173,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "final_df[final_df['CITY']=='Washington']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 171,
   "metadata": {},
   "outputs": [],
   "source": [
    "final_df.to_csv('../ct_csv/FinalCTTrialsDF_P1.csv')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Endpoint for entering ZIP codes:"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 204,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting uszipcode\n",
      "  Obtaining dependency information for uszipcode from https://files.pythonhosted.org/packages/b6/ba/a3e285c39363fe94c961cf483bd37064d19c454611d73c31dedd54e3373e/uszipcode-1.0.1-py2.py3-none-any.whl.metadata\n",
      "  Downloading uszipcode-1.0.1-py2.py3-none-any.whl.metadata (8.9 kB)\n",
      "Collecting geopy\n",
      "  Obtaining dependency information for geopy from https://files.pythonhosted.org/packages/e5/15/cf2a69ade4b194aa524ac75112d5caac37414b20a3a03e6865dfe0bd1539/geopy-2.4.1-py3-none-any.whl.metadata\n",
      "  Downloading geopy-2.4.1-py3-none-any.whl.metadata (6.8 kB)\n",
      "Requirement already satisfied: attrs in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from uszipcode) (23.1.0)\n",
      "Requirement already satisfied: requests in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from uszipcode) (2.31.0)\n",
      "Collecting pathlib-mate (from uszipcode)\n",
      "  Obtaining dependency information for pathlib-mate from https://files.pythonhosted.org/packages/5e/0f/6b6342767cb06562f4d67295191cd5c63775c04765766499a70265388db6/pathlib_mate-1.3.2-py3-none-any.whl.metadata\n",
      "  Downloading pathlib_mate-1.3.2-py3-none-any.whl.metadata (8.4 kB)\n",
      "Collecting atomicwrites (from uszipcode)\n",
      "  Downloading atomicwrites-1.4.1.tar.gz (14 kB)\n",
      "  Preparing metadata (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25hCollecting fuzzywuzzy (from uszipcode)\n",
      "  Obtaining dependency information for fuzzywuzzy from https://files.pythonhosted.org/packages/43/ff/74f23998ad2f93b945c0309f825be92e04e0348e062026998b5eefef4c33/fuzzywuzzy-0.18.0-py2.py3-none-any.whl.metadata\n",
      "  Downloading fuzzywuzzy-0.18.0-py2.py3-none-any.whl.metadata (4.9 kB)\n",
      "Collecting haversine>=2.5.0 (from uszipcode)\n",
      "  Obtaining dependency information for haversine>=2.5.0 from https://files.pythonhosted.org/packages/5b/f1/b7274966f0b5b665d9114e86d09c6bc87d241781d63d8817323dcfa940c6/haversine-2.8.1-py2.py3-none-any.whl.metadata\n",
      "  Downloading haversine-2.8.1-py2.py3-none-any.whl.metadata (5.9 kB)\n",
      "Requirement already satisfied: SQLAlchemy>=1.4.0 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from uszipcode) (2.0.19)\n",
      "Collecting sqlalchemy-mate>=1.4.28.3 (from uszipcode)\n",
      "  Obtaining dependency information for sqlalchemy-mate>=1.4.28.3 from https://files.pythonhosted.org/packages/8c/db/92f294181a7498696ae8de3cdc2ae06e75c1b19c62a45c9a692f594cb133/sqlalchemy_mate-1.4.28.4-py2.py3-none-any.whl.metadata\n",
      "  Downloading sqlalchemy_mate-1.4.28.4-py2.py3-none-any.whl.metadata (10 kB)\n",
      "Collecting geographiclib<3,>=1.52 (from geopy)\n",
      "  Obtaining dependency information for geographiclib<3,>=1.52 from https://files.pythonhosted.org/packages/9f/5a/a26132406f1f40cf51ea349a5f11b0a46cec02a2031ff82e391c2537247a/geographiclib-2.0-py3-none-any.whl.metadata\n",
      "  Downloading geographiclib-2.0-py3-none-any.whl.metadata (1.4 kB)\n",
      "Requirement already satisfied: typing-extensions>=4.2.0 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from SQLAlchemy>=1.4.0->uszipcode) (4.7.1)\n",
      "Collecting SQLAlchemy>=1.4.0 (from uszipcode)\n",
      "  Downloading SQLAlchemy-1.4.52.tar.gz (8.5 MB)\n",
      "\u001b[2K     \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m8.5/8.5 MB\u001b[0m \u001b[31m6.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m00:01\u001b[0m00:01\u001b[0m\n",
      "\u001b[?25h  Preparing metadata (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25hCollecting prettytable (from sqlalchemy-mate>=1.4.28.3->uszipcode)\n",
      "  Obtaining dependency information for prettytable from https://files.pythonhosted.org/packages/3d/c4/a32f4bf44faf95accbbd5d7864ddef9e289749a8efbc3adaad4a4671779a/prettytable-3.10.0-py3-none-any.whl.metadata\n",
      "  Downloading prettytable-3.10.0-py3-none-any.whl.metadata (30 kB)\n",
      "Requirement already satisfied: charset-normalizer<4,>=2 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from requests->uszipcode) (3.2.0)\n",
      "Requirement already satisfied: idna<4,>=2.5 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from requests->uszipcode) (3.4)\n",
      "Requirement already satisfied: urllib3<3,>=1.21.1 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from requests->uszipcode) (2.0.4)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from requests->uszipcode) (2023.7.22)\n",
      "Requirement already satisfied: wcwidth in /Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages (from prettytable->sqlalchemy-mate>=1.4.28.3->uszipcode) (0.2.6)\n",
      "Downloading uszipcode-1.0.1-py2.py3-none-any.whl (35 kB)\n",
      "Using cached geopy-2.4.1-py3-none-any.whl (125 kB)\n",
      "Using cached geographiclib-2.0-py3-none-any.whl (40 kB)\n",
      "Downloading haversine-2.8.1-py2.py3-none-any.whl (7.7 kB)\n",
      "Downloading sqlalchemy_mate-1.4.28.4-py2.py3-none-any.whl (77 kB)\n",
      "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m77.1/77.1 kB\u001b[0m \u001b[31m4.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hDownloading fuzzywuzzy-0.18.0-py2.py3-none-any.whl (18 kB)\n",
      "Downloading pathlib_mate-1.3.2-py3-none-any.whl (56 kB)\n",
      "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m57.0/57.0 kB\u001b[0m \u001b[31m4.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
      "\u001b[?25hDownloading prettytable-3.10.0-py3-none-any.whl (28 kB)\n",
      "Building wheels for collected packages: SQLAlchemy, atomicwrites\n",
      "  Building wheel for SQLAlchemy (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for SQLAlchemy: filename=SQLAlchemy-1.4.52-cp39-cp39-macosx_11_0_arm64.whl size=1571647 sha256=59b242f2aa7ae1df69f2a6f529ce93e2b69a6217824207b372f530ed3fd6e202\n",
      "  Stored in directory: /Users/suryabhosale/Library/Caches/pip/wheels/e4/69/86/8d8c71b3e77855f96ea974fd488549c4ea1fe9d7122fbe2d7c\n",
      "  Building wheel for atomicwrites (setup.py) ... \u001b[?25ldone\n",
      "\u001b[?25h  Created wheel for atomicwrites: filename=atomicwrites-1.4.1-py2.py3-none-any.whl size=6944 sha256=6e7ab991a3605fd6fa19d29b6bfd3110fe8c9164909a6f5233d7106914ecffa0\n",
      "  Stored in directory: /Users/suryabhosale/Library/Caches/pip/wheels/2a/b5/06/d2f34584f352e4af7d1d7ac1baf38b5d24142c8044cd024fd5\n",
      "Successfully built SQLAlchemy atomicwrites\n",
      "Installing collected packages: fuzzywuzzy, SQLAlchemy, prettytable, pathlib-mate, haversine, geographiclib, atomicwrites, sqlalchemy-mate, geopy, uszipcode\n",
      "  Attempting uninstall: SQLAlchemy\n",
      "    Found existing installation: SQLAlchemy 2.0.19\n",
      "    Uninstalling SQLAlchemy-2.0.19:\n",
      "      Successfully uninstalled SQLAlchemy-2.0.19\n",
      "Successfully installed SQLAlchemy-1.4.52 atomicwrites-1.4.1 fuzzywuzzy-0.18.0 geographiclib-2.0 geopy-2.4.1 haversine-2.8.1 pathlib-mate-1.3.2 prettytable-3.10.0 sqlalchemy-mate-1.4.28.4 uszipcode-1.0.1\n"
     ]
    }
   ],
   "source": [
    "!pip install uszipcode geopy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 205,
   "metadata": {},
   "outputs": [],
   "source": [
    "from uszipcode import SearchEngine\n",
    "from geopy.distance import geodesic"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 210,
   "metadata": {},
   "outputs": [],
   "source": [
    "search = SearchEngine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 211,
   "metadata": {},
   "outputs": [],
   "source": [
    "zip_info = search.by_zipcode(11205)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "metadata": {},
   "outputs": [],
   "source": [
    "center_lat = zip_info.lat\n",
    "center_lon = zip_info.lng"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 215,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Exception ignored in: <function SearchEngine.__del__ at 0x1699af8b0>\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/suryabhosale/miniforge3/envs/langchain/lib/python3.9/site-packages/uszipcode/search.py\", line 195, in __del__\n",
      "    if self.ses:\n",
      "AttributeError: 'SearchEngine' object has no attribute 'ses'\n"
     ]
    }
   ],
   "source": [
    "nearby_zip_codes = search.by_coordinates(center_lat, center_lon, radius=100, returns=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "num_closest = 100\n",
    "distances = []\n",
    "for zip_info in nearby_zip_codes:\n",
    "    if zip_info.lat and zip_info.lng:  # Some zip codes might lack lat/lon info\n",
    "        distance = geodesic((center_lat, center_lon), (zip_info.lat, zip_info.lng)).miles\n",
    "        distances.append((zip_info.zipcode, distance))\n",
    "\n",
    "# Sort zip codes by distance and return the closest ones\n",
    "closest_zip_codes = sorted(distances, key=lambda x: x[1])[:num_closest]\n",
    "for zip , distance in closest_zip_codes:\n",
    "    print(round(distance,2))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Function to find the closest zip_codes for a user input zipcode"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 226,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_closest_zip_codes(zip_code:int, num_closest:int=100, radius=100):\n",
    "    distances = []\n",
    "    search_engine = SearchEngine()\n",
    "    zip_info = search_engine.by_zipcode(zip_code)\n",
    "    center_lat, center_lon = zip_info.lat, zip_info.lng\n",
    "    nearby_zip_codes = search_engine.by_coordinates(center_lat, center_lon, radius=radius, returns=0)\n",
    "    for zip_instance in nearby_zip_codes:\n",
    "        if zip_instance.lat and zip_instance.lng:\n",
    "            distance = geodesic((center_lat, center_lon), (zip_instance.lat, zip_instance.lng)).miles\n",
    "            distances.append((zip_instance.zipcode, distance))\n",
    "    closest_zip_codes = [(item[0], round(item[1], 2)) for item in sorted(distances, key=lambda x: x[1])[:num_closest]]\n",
    "    return closest_zip_codes    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 228,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[('11205', 0.0), ('11240', 0.53), ('11217', 0.87), ('11238', 0.87), ('11201', 1.05), ('11216', 1.26), ('11206', 1.72), ('10002', 1.73), ('10041', 1.73), ('10045', 1.73), ('10055', 1.73), ('10060', 1.73), ('10090', 1.73), ('10095', 1.73), ('10104', 1.73), ('10105', 1.73), ('10106', 1.73), ('10107', 1.73), ('10118', 1.73), ('10120', 1.73), ('10121', 1.73), ('10122', 1.73), ('10123', 1.73), ('10151', 1.73), ('10155', 1.73), ('10158', 1.73), ('10161', 1.73), ('10166', 1.73), ('10175', 1.73), ('10176', 1.73), ('10178', 1.73), ('10260', 1.73), ('10265', 1.73), ('10270', 1.73), ('10281', 1.73), ('11211', 1.73), ('10015', 2.09), ('10038', 2.09), ('10099', 2.09), ('11213', 2.09), ('11221', 2.1), ('11231', 2.21), ('11215', 2.32), ('11225', 2.32), ('10005', 2.51), ('10006', 2.51), ('10007', 2.51), ('10048', 2.51), ('10271', 2.51), ('10279', 2.51), ('10013', 2.6), ('10278', 2.6), ('10004', 2.63), ('11237', 2.72), ('11233', 2.72), ('10009', 2.81), ('11226', 2.81), ('11232', 2.95), ('10003', 2.95), ('11222', 2.95), ('10280', 2.97), ('10012', 3.18), ('10282', 3.34), ('07309', 3.44), ('10014', 3.47), ('10010', 3.49), ('11218', 3.49), ('07311', 3.77), ('11212', 3.77), ('10011', 3.79), ('11203', 3.79), ('11241', 3.79), ('11242', 3.79), ('11243', 3.79), ('11249', 3.79), ('11252', 3.79), ('11256', 3.79), ('11101', 4.04), ('10017', 4.14), ('10167', 4.14), ('10016', 4.17), ('10110', 4.17), ('10165', 4.17), ('10168', 4.17), ('10169', 4.17), ('10170', 4.17), ('10173', 4.17), ('10174', 4.17), ('11109', 4.17), ('11378', 4.22), ('11385', 4.26), ('10098', 4.27), ('10119', 4.27), ('11210', 4.27), ('11104', 4.34), ('11220', 4.34), ('11207', 4.42), ('10001', 4.43), ('10199', 4.43), ('11219', 4.43)]\n"
     ]
    }
   ],
   "source": [
    "get_closest_zip_codes(11205)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 246,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "temp_df = pd.read_csv('../check.csv')\n",
    "# temp_df.ZIP[17929]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 239,
   "metadata": {},
   "outputs": [],
   "source": [
    "temp_df.ZIP.dropna(inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 247,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0      <class 'str'>\n",
       "1      <class 'str'>\n",
       "2      <class 'str'>\n",
       "3      <class 'str'>\n",
       "4      <class 'str'>\n",
       "           ...      \n",
       "340    <class 'str'>\n",
       "341    <class 'str'>\n",
       "342    <class 'str'>\n",
       "343    <class 'str'>\n",
       "344    <class 'str'>\n",
       "Name: ZIP, Length: 345, dtype: object"
      ]
     },
     "execution_count": 247,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "temp_df.dropna(subset=['ZIP']).ZIP.apply(type)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 248,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.3</th>\n",
       "      <th>Unnamed: 0.2</th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>...</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>FACILITY</th>\n",
       "      <th>CITY</th>\n",
       "      <th>STATE</th>\n",
       "      <th>ZIP</th>\n",
       "      <th>COUNTRY</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>7744</td>\n",
       "      <td>7744</td>\n",
       "      <td>7744</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>Anchorage Associates in Radiation Medicine</td>\n",
       "      <td>Anchorage</td>\n",
       "      <td>Alaska</td>\n",
       "      <td>98508</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>242</td>\n",
       "      <td>7986</td>\n",
       "      <td>7986</td>\n",
       "      <td>7986</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>University of Oklahoma Health Sciences Center</td>\n",
       "      <td>Oklahoma City</td>\n",
       "      <td>Oklahoma</td>\n",
       "      <td>73104</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>220</td>\n",
       "      <td>7964</td>\n",
       "      <td>7964</td>\n",
       "      <td>7964</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>Oncology Hematology Care Inc-Kenwood</td>\n",
       "      <td>Cincinnati</td>\n",
       "      <td>Ohio</td>\n",
       "      <td>45236</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>219</td>\n",
       "      <td>7963</td>\n",
       "      <td>7963</td>\n",
       "      <td>7963</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>Miami Valley Hospital South</td>\n",
       "      <td>Centerville</td>\n",
       "      <td>Ohio</td>\n",
       "      <td>45459</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>218</td>\n",
       "      <td>7962</td>\n",
       "      <td>7962</td>\n",
       "      <td>7962</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>Dayton Physicians LLC-Miami Valley South</td>\n",
       "      <td>Centerville</td>\n",
       "      <td>Ohio</td>\n",
       "      <td>45459</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>340</th>\n",
       "      <td>341</td>\n",
       "      <td>16554</td>\n",
       "      <td>16554</td>\n",
       "      <td>16554</td>\n",
       "      <td>NCT04335292</td>\n",
       "      <td>Osimertinib Then Chemotherapy in EGFR-mutated ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04335292</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>January 6, 2021</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include Progression Free Su...</td>\n",
       "      <td>Interventions include first-line treatment wit...</td>\n",
       "      <td>Durham Regional Cancer Centre, Lakeridge Health</td>\n",
       "      <td>Oshawa</td>\n",
       "      <td>Ontario</td>\n",
       "      <td>L1G 2B9</td>\n",
       "      <td>Canada</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.807129</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>341</th>\n",
       "      <td>342</td>\n",
       "      <td>16555</td>\n",
       "      <td>16555</td>\n",
       "      <td>16555</td>\n",
       "      <td>NCT04335292</td>\n",
       "      <td>Osimertinib Then Chemotherapy in EGFR-mutated ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04335292</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>January 6, 2021</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include Progression Free Su...</td>\n",
       "      <td>Interventions include first-line treatment wit...</td>\n",
       "      <td>The Ottawa Hospital</td>\n",
       "      <td>Ottawa</td>\n",
       "      <td>Ontario</td>\n",
       "      <td>K1H 8L6</td>\n",
       "      <td>Canada</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.807129</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>342</th>\n",
       "      <td>343</td>\n",
       "      <td>16556</td>\n",
       "      <td>16556</td>\n",
       "      <td>16556</td>\n",
       "      <td>NCT04335292</td>\n",
       "      <td>Osimertinib Then Chemotherapy in EGFR-mutated ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04335292</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>January 6, 2021</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include Progression Free Su...</td>\n",
       "      <td>Interventions include first-line treatment wit...</td>\n",
       "      <td>Sunnybrook Research Institute</td>\n",
       "      <td>Toronto</td>\n",
       "      <td>Ontario</td>\n",
       "      <td>M4N 3M5</td>\n",
       "      <td>Canada</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.807129</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>343</th>\n",
       "      <td>344</td>\n",
       "      <td>16557</td>\n",
       "      <td>16557</td>\n",
       "      <td>16557</td>\n",
       "      <td>NCT04335292</td>\n",
       "      <td>Osimertinib Then Chemotherapy in EGFR-mutated ...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04335292</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>January 6, 2021</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the Objective Response ...</td>\n",
       "      <td>Secondary outcomes include Progression Free Su...</td>\n",
       "      <td>Interventions include first-line treatment wit...</td>\n",
       "      <td>Princess Margaret Hospital</td>\n",
       "      <td>Toronto</td>\n",
       "      <td>Ontario</td>\n",
       "      <td>M5G 2M9</td>\n",
       "      <td>Canada</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.807129</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>344</th>\n",
       "      <td>334</td>\n",
       "      <td>15104</td>\n",
       "      <td>15104</td>\n",
       "      <td>15104</td>\n",
       "      <td>NCT04780568</td>\n",
       "      <td>Osimertinib and Tegavivint as First-Line Thera...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT04780568</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Metastatic Lung Non-Small Cell Carcinoma, Stag...</td>\n",
       "      <td>January 18, 2022</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is to determine the maximu...</td>\n",
       "      <td>Secondary outcomes include assessing the overa...</td>\n",
       "      <td>The intervention involves experimental treatme...</td>\n",
       "      <td>Ohio State University Comprehensive Cancer Center</td>\n",
       "      <td>Columbus</td>\n",
       "      <td>Ohio</td>\n",
       "      <td>43210</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.805296</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>345 rows × 23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0.3  Unnamed: 0.2  Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "0               0          7744          7744        7744  NCT03191149   \n",
       "1             242          7986          7986        7986  NCT03191149   \n",
       "2             220          7964          7964        7964  NCT03191149   \n",
       "3             219          7963          7963        7963  NCT03191149   \n",
       "4             218          7962          7962        7962  NCT03191149   \n",
       "..            ...           ...           ...         ...          ...   \n",
       "340           341         16554         16554       16554  NCT04335292   \n",
       "341           342         16555         16555       16555  NCT04335292   \n",
       "342           343         16556         16556       16556  NCT04335292   \n",
       "343           344         16557         16557       16557  NCT04335292   \n",
       "344           334         15104         15104       15104  NCT04780568   \n",
       "\n",
       "                                           STUDY_TITLE  \\\n",
       "0    Osimertinib in Treating Patients With Stage II...   \n",
       "1    Osimertinib in Treating Patients With Stage II...   \n",
       "2    Osimertinib in Treating Patients With Stage II...   \n",
       "3    Osimertinib in Treating Patients With Stage II...   \n",
       "4    Osimertinib in Treating Patients With Stage II...   \n",
       "..                                                 ...   \n",
       "340  Osimertinib Then Chemotherapy in EGFR-mutated ...   \n",
       "341  Osimertinib Then Chemotherapy in EGFR-mutated ...   \n",
       "342  Osimertinib Then Chemotherapy in EGFR-mutated ...   \n",
       "343  Osimertinib Then Chemotherapy in EGFR-mutated ...   \n",
       "344  Osimertinib and Tegavivint as First-Line Thera...   \n",
       "\n",
       "                                            STUDY_URL STUDY_STATUS  \\\n",
       "0    https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "1    https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "2    https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "3    https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "4    https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "..                                                ...          ...   \n",
       "340  https://www.clinicaltrials.gov/study/NCT04335292   Recruiting   \n",
       "341  https://www.clinicaltrials.gov/study/NCT04335292   Recruiting   \n",
       "342  https://www.clinicaltrials.gov/study/NCT04335292   Recruiting   \n",
       "343  https://www.clinicaltrials.gov/study/NCT04335292   Recruiting   \n",
       "344  https://www.clinicaltrials.gov/study/NCT04780568   Recruiting   \n",
       "\n",
       "                                            CONDITIONS        START_DATE  ...  \\\n",
       "0    Advanced Lung Non-Small Cell Carcinoma, Recurr...    April 25, 2018  ...   \n",
       "1    Advanced Lung Non-Small Cell Carcinoma, Recurr...    April 25, 2018  ...   \n",
       "2    Advanced Lung Non-Small Cell Carcinoma, Recurr...    April 25, 2018  ...   \n",
       "3    Advanced Lung Non-Small Cell Carcinoma, Recurr...    April 25, 2018  ...   \n",
       "4    Advanced Lung Non-Small Cell Carcinoma, Recurr...    April 25, 2018  ...   \n",
       "..                                                 ...               ...  ...   \n",
       "340                         Non-Small Cell Lung Cancer   January 6, 2021  ...   \n",
       "341                         Non-Small Cell Lung Cancer   January 6, 2021  ...   \n",
       "342                         Non-Small Cell Lung Cancer   January 6, 2021  ...   \n",
       "343                         Non-Small Cell Lung Cancer   January 6, 2021  ...   \n",
       "344  Metastatic Lung Non-Small Cell Carcinoma, Stag...  January 18, 2022  ...   \n",
       "\n",
       "                                      PRIMARY_OUTCOMES  \\\n",
       "0    The primary outcome is the best objective resp...   \n",
       "1    The primary outcome is the best objective resp...   \n",
       "2    The primary outcome is the best objective resp...   \n",
       "3    The primary outcome is the best objective resp...   \n",
       "4    The primary outcome is the best objective resp...   \n",
       "..                                                 ...   \n",
       "340  The primary outcome is the Objective Response ...   \n",
       "341  The primary outcome is the Objective Response ...   \n",
       "342  The primary outcome is the Objective Response ...   \n",
       "343  The primary outcome is the Objective Response ...   \n",
       "344  The primary outcome is to determine the maximu...   \n",
       "\n",
       "                                    SECONDARY_OUTCOMES  \\\n",
       "0    Secondary outcomes include progression-free su...   \n",
       "1    Secondary outcomes include progression-free su...   \n",
       "2    Secondary outcomes include progression-free su...   \n",
       "3    Secondary outcomes include progression-free su...   \n",
       "4    Secondary outcomes include progression-free su...   \n",
       "..                                                 ...   \n",
       "340  Secondary outcomes include Progression Free Su...   \n",
       "341  Secondary outcomes include Progression Free Su...   \n",
       "342  Secondary outcomes include Progression Free Su...   \n",
       "343  Secondary outcomes include Progression Free Su...   \n",
       "344  Secondary outcomes include assessing the overa...   \n",
       "\n",
       "                                         INTERVENTIONS  \\\n",
       "0    Participants will receive osimertinib orally o...   \n",
       "1    Participants will receive osimertinib orally o...   \n",
       "2    Participants will receive osimertinib orally o...   \n",
       "3    Participants will receive osimertinib orally o...   \n",
       "4    Participants will receive osimertinib orally o...   \n",
       "..                                                 ...   \n",
       "340  Interventions include first-line treatment wit...   \n",
       "341  Interventions include first-line treatment wit...   \n",
       "342  Interventions include first-line treatment wit...   \n",
       "343  Interventions include first-line treatment wit...   \n",
       "344  The intervention involves experimental treatme...   \n",
       "\n",
       "                                              FACILITY           CITY  \\\n",
       "0           Anchorage Associates in Radiation Medicine      Anchorage   \n",
       "1        University of Oklahoma Health Sciences Center  Oklahoma City   \n",
       "2                 Oncology Hematology Care Inc-Kenwood     Cincinnati   \n",
       "3                          Miami Valley Hospital South    Centerville   \n",
       "4             Dayton Physicians LLC-Miami Valley South    Centerville   \n",
       "..                                                 ...            ...   \n",
       "340    Durham Regional Cancer Centre, Lakeridge Health         Oshawa   \n",
       "341                                The Ottawa Hospital         Ottawa   \n",
       "342                      Sunnybrook Research Institute        Toronto   \n",
       "343                         Princess Margaret Hospital        Toronto   \n",
       "344  Ohio State University Comprehensive Cancer Center       Columbus   \n",
       "\n",
       "        STATE      ZIP        COUNTRY  \\\n",
       "0      Alaska    98508  United States   \n",
       "1    Oklahoma    73104  United States   \n",
       "2        Ohio    45236  United States   \n",
       "3        Ohio    45459  United States   \n",
       "4        Ohio    45459  United States   \n",
       "..        ...      ...            ...   \n",
       "340   Ontario  L1G 2B9         Canada   \n",
       "341   Ontario  K1H 8L6         Canada   \n",
       "342   Ontario  M4N 3M5         Canada   \n",
       "343   Ontario  M5G 2M9         Canada   \n",
       "344      Ohio    43210  United States   \n",
       "\n",
       "                                      POINT_OF_CONTACT     score  \n",
       "0    {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "1    {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "2    {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "3    {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "4    {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "..                                                 ...       ...  \n",
       "340  {'Name': None, 'Organization': None, 'Email': ...  0.807129  \n",
       "341  {'Name': None, 'Organization': None, 'Email': ...  0.807129  \n",
       "342  {'Name': None, 'Organization': None, 'Email': ...  0.807129  \n",
       "343  {'Name': None, 'Organization': None, 'Email': ...  0.807129  \n",
       "344  {'Name': None, 'Organization': None, 'Email': ...  0.805296  \n",
       "\n",
       "[345 rows x 23 columns]"
      ]
     },
     "execution_count": 248,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "temp_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 249,
   "metadata": {},
   "outputs": [],
   "source": [
    "temp_zip_list = ['11205', '11240', '11217', '11238', '11201', '11216', '11206', '10002', '10041', '10045', '10055', '10060', '10090', '10095', '10104', '10105', '10106', '10107', '10118', '10120', '10121', '10122', '10123', '10151', '10155', '10158', '10161', '10166', '10175', '10176', '10178', '10260', '10265', '10270', '10281', '11211', '10015', '10038', '10099', '11213', '11221', '11231', '11215', '11225', '10005', '10006', '10007', '10048', '10271', '10279', '10013', '10278', '10004', '11237', '11233', '10009', '11226', '11232', '10003', '11222', '10280', '10012', '10282', '07309', '10014', '10010', '11218', '07311', '11212', '10011', '11203', '11241', '11242', '11243', '11249', '11252', '11256', '11101', '10017', '10167', '10016', '10110', '10165', '10168', '10169', '10170', '10173', '10174', '11109', '11378', '11385', '10098', '10119', '11210', '11104', '11220', '11207', '10001', '10199', '11219', '07310', '07302', '11230', '10022', '10152', '10153', '10154', '10171', '10172', '10020', '10103', '10111', '10112', '10177', '10065', '11204', '07304', '11379', '10018', '10036', '10044', '11377', '11236', '07030', '11106', '11228', '11208', '11239', '10021', '10019', '10075', '10162', '10200', '11103', '11209', '07305', '11373', '11102', '07306', '07086', '11374', '11223', '10023', '07307', '11372', '10069', '10028', '10128', '11421', '11416', '07087', '11234', '11214', '11229', '11369', '11418', '11417', '11370', '11105', '10029', '11375', '11414', '11368', '07093', '07047', '11415', '10301', '10024', '10025', '11371', '07002', '10026', '11224', '11235', '07094', '11367', '10035', '11419', '10305', '10115', '10027', '10304', '07022', '10037', '11435', '07032', '11420', '10454', '11354', '10455', '11355', '10310', '11436', '07020', '07010', '10030', '07105', '10451', '11356', '11433', '11697', '10474', '11351', '11432', '10031', '10039', '10302', '11366', '11430', '07657', '11434', '11365', '07029', '07073', '07072', '11358', '10456', '11694', '07650', '07031', '10032', '07201', '10459', '07071', '10473', '10452', '07114', '07070', '11357', '11693', '07643', '10472', '07024', '07102', '11423', '07074', '10033', '10303', '07660', '10453', '11412', '11361', '10465', '10460', '10457', '11692', '10306', '07206', '11413', '11360', '11364', '07605', '10462', '07104', '11427', '10040', '07608', '07109', '11359', '11429', '10314', '07108', '11428', '07606', '10311', '07075', '10458', '07107', '11096', '07103', '07110', '11411', '11691', '07112', '10034', '11422', '11363', '07603', '07604', '10468', '07057', '10461', '11362', '07014', '07632', '11516', '07666', '07202', '11581', '10467', '10463', '07018', '10308', '07055', '11426', '07601', '07205', '07208', '07017', '11598', '07003', '07631', '07111', '10469', '11021', '07106', '11004', '07026', '11003', '07028', '07644', '11001', '11580', '11509', '07050', '11005', '07036', '10312', '11023', '11020', '10470', '07012', '10471', '11042', '11559', '11024', '07013', '11557', '10466', '07008', '07670', '07083', '07607', '10464', '10475', '07042', '11040', '07203', '07079', '11010', '07663', '07204', '11565', '07011', '07043', '07621', '07040', '11563', '11030', '07662', '07407', '07661', '07033', '10705', '10550', '11518', '07052', '10803', '07646', '11552', '10704', '07064', '07088', '10553', '07009', '07044', '10309', '07626', '07628', '07503', '07065', '07041', '11530', '11599', '10552', '07001', '07016', '10805', '07504', '11050', '07424', '11501', '07513', '07627', '11570', '11596', '07652', '07077', '07410', '07501', '07510', '11561', '11507', '10701', '07649', '11572', '07081', '11577', '11558', '11576', '07066', '07021', '07027', '07641', '10708', '07514', '10307', '11550', '07095', '07505', '10801', '11510', '07067', '07734', '07758', '07078', '10703', '07522', '07524', '07624', '11514', '07039', '07630', '07068', '07512', '07502', '10538', '07090', '07006', '08861', '11548', '07718', '08830', '07737', '10804', '11553', '07640', '10709', '07732', '11579', '10707', '07716', '07506', '10710', '07452', '07092', '11575', '07901', '07676', '11556', '08863', '11520', '10706', '07648', '11590', '11568', '07450', '11542', '07730', '07647', '07076', '07675', '11545', '10543', '07508', '07735', '07642', '07004', '08832', '07928', '07023', '07748', '07721', '07936', '11554', '11566', '07470', '08820', '07423', '07432', '10583', '07974', '08879', '07058', '07932', '10983', '10522', '07760', '10976', '08840', '07481', '07062', '10964', '07704', '10528', '10502', '07677', '11753', '07463', '07940']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 256,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0.3</th>\n",
       "      <th>Unnamed: 0.2</th>\n",
       "      <th>Unnamed: 0.1</th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>NCT_NUMBER</th>\n",
       "      <th>STUDY_TITLE</th>\n",
       "      <th>STUDY_URL</th>\n",
       "      <th>STUDY_STATUS</th>\n",
       "      <th>CONDITIONS</th>\n",
       "      <th>START_DATE</th>\n",
       "      <th>...</th>\n",
       "      <th>PRIMARY_OUTCOMES</th>\n",
       "      <th>SECONDARY_OUTCOMES</th>\n",
       "      <th>INTERVENTIONS</th>\n",
       "      <th>FACILITY</th>\n",
       "      <th>CITY</th>\n",
       "      <th>STATE</th>\n",
       "      <th>ZIP</th>\n",
       "      <th>COUNTRY</th>\n",
       "      <th>POINT_OF_CONTACT</th>\n",
       "      <th>score</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>7744</td>\n",
       "      <td>7744</td>\n",
       "      <td>7744</td>\n",
       "      <td>NCT03191149</td>\n",
       "      <td>Osimertinib in Treating Patients With Stage II...</td>\n",
       "      <td>https://www.clinicaltrials.gov/study/NCT03191149</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>Advanced Lung Non-Small Cell Carcinoma, Recurr...</td>\n",
       "      <td>April 25, 2018</td>\n",
       "      <td>...</td>\n",
       "      <td>The primary outcome is the best objective resp...</td>\n",
       "      <td>Secondary outcomes include progression-free su...</td>\n",
       "      <td>Participants will receive osimertinib orally o...</td>\n",
       "      <td>Anchorage Associates in Radiation Medicine</td>\n",
       "      <td>Anchorage</td>\n",
       "      <td>Alaska</td>\n",
       "      <td>98508</td>\n",
       "      <td>United States</td>\n",
       "      <td>{'Name': None, 'Organization': None, 'Email': ...</td>\n",
       "      <td>0.813524</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>1 rows × 23 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0.3  Unnamed: 0.2  Unnamed: 0.1  Unnamed: 0   NCT_NUMBER  \\\n",
       "0             0          7744          7744        7744  NCT03191149   \n",
       "\n",
       "                                         STUDY_TITLE  \\\n",
       "0  Osimertinib in Treating Patients With Stage II...   \n",
       "\n",
       "                                          STUDY_URL STUDY_STATUS  \\\n",
       "0  https://www.clinicaltrials.gov/study/NCT03191149   Recruiting   \n",
       "\n",
       "                                          CONDITIONS      START_DATE  ...  \\\n",
       "0  Advanced Lung Non-Small Cell Carcinoma, Recurr...  April 25, 2018  ...   \n",
       "\n",
       "                                    PRIMARY_OUTCOMES  \\\n",
       "0  The primary outcome is the best objective resp...   \n",
       "\n",
       "                                  SECONDARY_OUTCOMES  \\\n",
       "0  Secondary outcomes include progression-free su...   \n",
       "\n",
       "                                       INTERVENTIONS  \\\n",
       "0  Participants will receive osimertinib orally o...   \n",
       "\n",
       "                                     FACILITY       CITY   STATE    ZIP  \\\n",
       "0  Anchorage Associates in Radiation Medicine  Anchorage  Alaska  98508   \n",
       "\n",
       "         COUNTRY                                   POINT_OF_CONTACT     score  \n",
       "0  United States  {'Name': None, 'Organization': None, 'Email': ...  0.813524  \n",
       "\n",
       "[1 rows x 23 columns]"
      ]
     },
     "execution_count": 256,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "temp_df[temp_df['ZIP'].isin(temp_zip_list)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 255,
   "metadata": {},
   "outputs": [],
   "source": [
    "temp_zip_list.append('98508')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 257,
   "metadata": {},
   "outputs": [],
   "source": [
    "location = {'CITY': 'Chicago', 'STATE': 'Illinois', 'COUNTRY': 'United States'}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 259,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "SimpleZipcode(zipcode='60601', zipcode_type='STANDARD', major_city='Chicago', post_office_city='Chicago, IL', common_city_list=['Chicago'], county='Cook County', state='IL', lat=41.89, lng=-87.62, timezone='America/Chicago', radius_in_miles=0.7954545454545454, area_code_list='312,773,872', population=11110, population_density=28793.0, land_area_in_sqmi=0.39, water_area_in_sqmi=0.0, housing_units=8594, occupied_housing_units=6739, median_home_value=494200, median_household_income=95556, bounds_west=-87.633967, bounds_east=-87.61328, bounds_north=41.889045, bounds_south=41.880829)"
      ]
     },
     "execution_count": 259,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "location_info = search.by_city(location['CITY'])[0]\n",
    "location_info"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "center_lat = location_info.lat\n",
    "center_lon = location_info.lng"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "langchain",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
